DexCom (DXCM) : 8 brokerage houses believe that DexCom (DXCM) is a Strong Buy at current levels. 2 Analyst considers the fundamentals to be worthy of a Buy recommendation. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on DexCom (DXCM). Zacks Investment Research suggests a Hold with a rank of 3. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 13 Wall Street Analysts endorse the stock as a Buy with a rating of 1.73.
DexCom (DXCM) : 12 investment research analysts covering DexCom (DXCM) have an average price target of $96.4 for the near short term. The highest target price given by the Brokerage Firm to the stock is $115 and the lowest target is $57 for the short term. Analysts expect the variance to be within $15.65 of the average price.
Also, Equity Analysts at the Deutsche Bank maintains the rating on DexCom (NASDAQ:DXCM). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency raises the price target from $90 per share to $98 per share. The rating by the firm was issued on July 15, 2016.
DexCom (NASDAQ:DXCM): After opening at $91.52, the stock dipped to an intraday low of $90.81 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $93.85 and the buying power remained strong till the end. The stock closed at $92.75 for the day, a gain of 1.05% for the day session. The total traded volume was 583,576. The stocks close on the previous trading day was $91.79.
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4, DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patients receiver and an application on the patients iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers, who can remotely monitor a patients glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpots data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.